Compare Ecopetrol SA (EC) vs Nuvalent Inc (NUVL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ecopetrol SA vs Nuvalent Inc — how do they compare? Ecopetrol SA trades at $15.78 (market cap $30.44B), while Nuvalent Inc trades at $123.96 (market cap $9.81B). The key difference: Ecopetrol SA is far larger — about 3.1× Nuvalent Inc's market cap, and Ecopetrol SA pays a 4.06% dividend while Nuvalent Inc pays none. Which is the better fit depends on your goals.
| EC | NUVL | |
|---|---|---|
Market Cap | $30.44B | $9.81B |
Sector | Energy | Technology |
52-Week High | $16.58 | $123.96 |
52-Week Low | $8.29 | $72.16 |
Enterprise Value | $58.23B | $8.52B |
Dividend Yield | 4.06% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ecopetrol (EC) trades at $15.93, down 1.42% with mixed technical signals showing bullish moving averages but bearish oscillators. The company maintains solid profitability with 8.76% net margin and 13.01% ROE, though revenue has declined from $159.6B in 2022 to $119.7B in 2025. Recent developments include a collective bargaining agreement with workers and upcoming Q2 2026 earnings release on August 3, 2026.
While valuation appears reasonable with P/E of 11.39, declining revenue trends and recent earnings misses pose challenges. Analyst consensus is cautious with 54.55% hold rating and $14.63 price target below current levels. Key risks include oil price volatility and execution challenges in a competitive energy sector.
Nuvalent (NUVL) trades at $123.96, unchanged on the day, with a P/B ratio of 8.35 and negative profitability metrics. The stock is technically bullish based on moving averages, though oscillators are neutral. Recent news highlights GSK's proposed acquisition of Nuvalent for $124 per share, totaling $10.6 billion, announced on June 9, 2026 (Reuters). Earnings have been mixed, with two misses and one beat in the last three quarters.
The acquisition by GSK provides a near-term price floor but limits upside. Risks include ongoing financial losses and shareholder litigation questioning deal fairness. Analyst sentiment is mixed with 42% buy ratings. The stock's outlook hinges on deal completion, with fundamental challenges persisting until closure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ecopetrol SA
Ecopetrol SA is a vertically integrated oil company with operations in Latin America and the United States Gulf Coast. Based out of Colombia, the company explores, develops, and conducts production activities in various countries. Ecopetrol works as the primary operator or partner in a joint venture, in a host of assets held onshore and offshore. Along with production, the company refines and markets crude oils and byproducts produced from its fields. Crude products are moved by Ecopetrol through a series of pipelines throughout Colombia, along with a network of third-party production centers and facilities.
Read more on EC →About Nuvalent Inc
Nuvalent, Inc. is a clinical-stage oncology company focused on creating precisely targeted therapies for patients with cancers driven by specific gene mutations. The company leverages a deep understanding of structural biology and medicinal chemistry to design novel small-molecule kinase inhibitors to overcome resistance mechanisms in advanced solid tumors. Nuvalent is committed to developing its pipeline of candidates to address high unmet needs in the treatment of various cancers.
Read more on NUVL →
